Muutke küpsiste eelistusi

E-raamat: Lipids and the Kidney

Edited by , Edited by , Series edited by , Edited by
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 74,88 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
Lipids and the Kidney
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

During the past decade, experimental and clinical studies have suggested that dyslipidemia may be an important risk factor for the progression of renal disease. This volume explores in great detail recent advances in our understanding of the pathogenesis and treatment of this common complication of progressive renal injury. In the experimental investigations presented, emphasis is placed on specific disturbances of lipids that are seen in progressive renal disease including the effects of oxidatively modified lipoproteins and Lp(a) on various functions of the glomerular cells. Clinical studies have identified dyslipidemia as a risk factor for progressive renal disease in diabetes mellitus, various non-diabetic renal diseases, and most recently in patients with progressive renal allograft loss. An emerging interest in the genetics of dyslipidemia has recently arisen and this topic as it specifically relates to progressive renal disease is discussed. The final section of the book offers new insights into the mechanisms of action of antilipemic therapy used in the treatment of dyslipidemia. This volume should be read by all nephrologists caring for patients with progressive renal disease and by physicians interested in the biology of lipids, diabetes and essential hypertension.
Part 1 Lipids as a risk factor for renal disease: lipid abnormalities in
progressive renal insufficiency; hypertension, hyperlipidemia and
microalbuminuria; apolipoprotein E phenotype and renal disease; lipoprotein
glomerulopathy and its pathogenesis; cholesterol as a predictor of
progression in diabetic renal disease; cholesterol as a predictor of
progression in nondiabetic chronic renal disease; role of lipids in chronic
renal allograft rejection. Part 2 Treatment of dyslipidemia in patients with
renal disease: effect of lipid-lowering therapy on the progression of renal
disease in nondiabetic nephrotic patients; treatment of hyperlipidemia in
patients with non-insulin-dependent diabetes mellitus with progressive
nephropathy; effect of antiproteinuric treatment on the lipid profile in
nondiabetic renal disease; the effect of HMG-CoA reductase inhibitors on
chronic allograft rejection; long-term low-density lipoprotein
immunoapheresis in renal disease. Part 3 Mechanisms of lipid-induced renal
injury - experimental insights: role of lipids in progressive renal disease -
insights from the analbuminemic rat; hyperlipidemia and tissue contents of
N-sigma-(carboxymethyl)lysine in streptozotocin diabetes; effects of lipids
on glomerular fibrinolysis in vitro; effects of lipoprotein (a) on mesangial
cell biology; HMG-CoA reductase inhibitor suppression of glomerular cell
proliferation in rats with anti-thy-1.1 nephritis; the role of oxidatively
modified lipoproteins in lipid nephropathy; effect of low-density
lipoproteins on mesangial cell expression of monocyte chemoattractant
peptides. Part 4 New insights into effects of antilipemic therapy: regulation
of mesangial cell proliferation by the mevalonate pathway;
hypercholesterolemia and progressive kidney disease - the role of macrophages
and macrophage-derived products; central role of the transcription factor
nuclear factor-kB in mesangial cell production of chemokines; isoprenoids,
ras and proliferative glomerular disease.
Lisainfo e-raamatute kohta Lisainfo e-raamatute kohta
Püsilink: https://www.kriso.ee/db/97833180022322e.html
Märksõnad: